Additionally, MMP1 (PP4 = 0.92) and CCL4 (PP4 = 0.87) in the prefrontal cortex had the strongest colocalization evidence (PP4 > 0.85), suggesting they could potentially serve as novel therapeutic targets for AD. This evidence concerns the gene MMP1 and Alzheimer disease.